Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Targeting ephrin A3 in the bone marrow niche offers a promising therapeutic strategy to impede hematopoietic stem cell maintenance in MDS patients

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMarie GoulardRGRemisha GurungLALinda Ariza-McNaughton

Discussion

Loading...

Member takes

Overview

In vivo analysis reveals targeting bone marrow niche alters hematopoietic stem cells in MDS, suggesting new therapies.

Key Points

  • This research investigates the role of the bone marrow niche in maintaining hematopoietic stem cells (HSCs) in myelodysplastic syndrome (MDS).
  • Utilized a humanized bone marrow niche in immunodeficient mice for in vivo studies.
  • Conducted co-culture of hematopoietic stem and progenitor cells (HSPCs) from MDS patients with mesenchymal stromal cells (MSCs).
  • Employed bulk and single-cell RNA sequencing to analyze interactions between HSPCs and MSCs.
  • Performed siRNA knockdown of candidate genes in primary human MSCs to identify key interactions.
  • MDS HSPCs proliferated significantly more in direct contact with MSCs compared to trans-well conditions.
  • Knockdown of selected genes in MSCs induced apoptosis and growth arrest, impacting HSC maintenance.
  • IL10 regulation of EPHA3 expression was confirmed in MSCs, which was selectively expressed in MDS.
  • Targeting EPHA3 significantly reduced MDS HSPCs with minimal effect on healthy HSPCs.

Cite This Study

Goulard et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d977https://doi.org/10.1182/blood-2025-859
View Full Paper
Ask AI
Bookmark
Share